Effect of hepatic dysfunction on oral cyclosporin pharmacokinetics in
marrow transplant patients
GC Yee, MS Kennedy, R Storb and ED Thomas
The effect of hepatic dysfunction, defined as abnormal serum bilirubin
level, on oral cyclosporin (CSP) pharmacokinetics was examined in 28 marrow
transplant patients who received CSP for prophylaxis of graft-v- host
disease. Serum CSP concentrations were measured by radioimmunoassay.
Forty-one concentration-time courses were studied, divided among patients
with no (less than 1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0
to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by
elimination rate constant and clearance, was delayed in patients with
moderate hepatic dysfunction compared to those with no hepatic dysfunction
(P less than .05). The volume of distribution, lag time for absorption,
maximum serum concentration, and time at which the maximum concentration
was achieved was not affected by hepatic function. These data indicate that
patients with moderate hepatic dysfunction have delayed CSP or CSP
metabolite elimination and may be at higher risk for developing CSP-related
toxicity.
Volume 64,
Issue 6,
pp. 1277-1279,
12/01/1984
Copyright © 1984 by The American Society of Hematology
